These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 19568883)
1. Molecular biology of malignant mesothelioma. Sekido Y Environ Health Prev Med; 2008 Mar; 13(2):65-70. PubMed ID: 19568883 [TBL] [Abstract][Full Text] [Related]
2. Genomic abnormalities and signal transduction dysregulation in malignant mesothelioma cells. Sekido Y Cancer Sci; 2010 Jan; 101(1):1-6. PubMed ID: 19793348 [TBL] [Abstract][Full Text] [Related]
3. Molecular pathogenesis of malignant mesothelioma. Sekido Y Carcinogenesis; 2013 Jul; 34(7):1413-9. PubMed ID: 23677068 [TBL] [Abstract][Full Text] [Related]
4. A mouse model recapitulating molecular features of human mesothelioma. Altomare DA; Vaslet CA; Skele KL; De Rienzo A; Devarajan K; Jhanwar SC; McClatchey AI; Kane AB; Testa JR Cancer Res; 2005 Sep; 65(18):8090-5. PubMed ID: 16166281 [TBL] [Abstract][Full Text] [Related]
5. Similar tumor suppressor gene alteration profiles in asbestos-induced murine and human mesothelioma. Lecomte C; Andujar P; Renier A; Kheuang L; Abramowski V; Mellottee L; Fleury-Feith J; Zucman-Rossi J; Giovannini M; Jaurand MC Cell Cycle; 2005 Dec; 4(12):1862-9. PubMed ID: 16319530 [TBL] [Abstract][Full Text] [Related]
6. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Hirao T; Bueno R; Chen CJ; Gordon GJ; Heilig E; Kelsey KT Carcinogenesis; 2002 Jul; 23(7):1127-30. PubMed ID: 12117769 [TBL] [Abstract][Full Text] [Related]
7. Cytogenetic and molecular genetic changes in malignant mesothelioma. Musti M; Kettunen E; Dragonieri S; Lindholm P; Cavone D; Serio G; Knuutila S Cancer Genet Cytogenet; 2006 Oct; 170(1):9-15. PubMed ID: 16965949 [TBL] [Abstract][Full Text] [Related]
8. Asbestos, chromosomal deletions, and tumor suppressor gene alterations in human malignant mesothelioma. Murthy SS; Testa JR J Cell Physiol; 1999 Aug; 180(2):150-7. PubMed ID: 10395284 [TBL] [Abstract][Full Text] [Related]
9. Advances in the molecular biology of malignant mesothelioma. Toyooka S; Kishimoto T; Date H Acta Med Okayama; 2008 Feb; 62(1):1-7. PubMed ID: 18323865 [TBL] [Abstract][Full Text] [Related]
10. Activated TNF-alpha/NF-kappaB signaling via down-regulation of Fas-associated factor 1 in asbestos-induced mesotheliomas from Arf knockout mice. Altomare DA; Menges CW; Pei J; Zhang L; Skele-Stump KL; Carbone M; Kane AB; Testa JR Proc Natl Acad Sci U S A; 2009 Mar; 106(9):3420-5. PubMed ID: 19223589 [TBL] [Abstract][Full Text] [Related]
11. INK4a-ARF alterations and p53 mutations in hepatocellular carcinomas. Tannapfel A; Busse C; Weinans L; Benicke M; Katalinic A; Geissler F; Hauss J; Wittekind C Oncogene; 2001 Oct; 20(48):7104-9. PubMed ID: 11704835 [TBL] [Abstract][Full Text] [Related]
12. The role of key genes and pathways involved in the tumorigenesis of Malignant Mesothelioma. de Assis LV; Locatelli J; Isoldi MC Biochim Biophys Acta; 2014 Apr; 1845(2):232-47. PubMed ID: 24491449 [TBL] [Abstract][Full Text] [Related]
14. Interphase fish analysis of cell cycle genes in asbestos-treated human mesothelial cells (HMC), SV40-transformed HMC (MeT-5A) and mesothelioma cells (COLO). Dopp E; Poser I; Papp T Cell Mol Biol (Noisy-le-grand); 2002; 48 Online Pub():OL271-7. PubMed ID: 12643444 [TBL] [Abstract][Full Text] [Related]
15. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma. Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014 [TBL] [Abstract][Full Text] [Related]
16. High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Bianchi AB; Mitsunaga SI; Cheng JQ; Klein WM; Jhanwar SC; Seizinger B; Kley N; Klein-Szanto AJ; Testa JR Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10854-8. PubMed ID: 7479897 [TBL] [Abstract][Full Text] [Related]
17. INK4a/ARF locus alterations in human non-Hodgkin's lymphomas mainly occur in tumors with wild-type p53 gene. Pinyol M; Hernández L; Martínez A; Cobo F; Hernández S; Beà S; López-Guillermo A; Nayach I; Palacín A; Nadal A; Fernández PL; Montserrat E; Cardesa A; Campo E Am J Pathol; 2000 Jun; 156(6):1987-96. PubMed ID: 10854221 [TBL] [Abstract][Full Text] [Related]
18. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Gottfried ON; Viskochil DH; Couldwell WT Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723 [TBL] [Abstract][Full Text] [Related]
19. Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients. Kitamura F; Araki S; Suzuki Y; Yokoyama K; Tanigawa T; Iwasaki R Ind Health; 2002 Apr; 40(2):175-81. PubMed ID: 12064559 [TBL] [Abstract][Full Text] [Related]
20. Alterations of the INK4a-ARF gene locus in pleomorphic adenoma of the parotid gland. Weber A; Langhanki L; Schütz A; Wittekind C; Bootz F; Tannapfel A J Pathol; 2002 Nov; 198(3):326-34. PubMed ID: 12375265 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]